104535-37-7

Basic information

• Product Name: 3,4-DIHYDRO-2H-1,4-BENZOXAZIN-7-OL
• Synonyms: 3,4-DIHYDRO-2H-1,4-BENZOXAZIN-7-OL;3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ol;3,4-Dihydro-2H-benzo[1,4]oxazin-7-ol;2H-1,4-BENZOXAZIN-7-OL, 3,4-DIHYDRO-
• CAS NO: 104535-37-7
• Molecular Formula: C₈H₉NO₂
• Molecular Weight: 151.16
• Mol File: 104535-37-7.mol

Chemical Properties

• Appearance: white powder
• Density: 1.241
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3,4-DIHYDRO-2H-1,4-BENZOXAZIN-7-OL(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-DIHYDRO-2H-1,4-BENZOXAZIN-7-OL(104535-37-7)
• EPA Substance Registry System: 3,4-DIHYDRO-2H-1,4-BENZOXAZIN-7-OL(104535-37-7)

Safety Data

• Hazardous Substances Data: 104535-37-7(Hazardous Substances Data)

Usage

Uses

Used in Crop Protection:
3,4-Dihydro-2H-1,4-benzoxazin-7-ol is used as a biopesticide in agriculture for its insecticidal properties against various pests. It helps protect crops from damage caused by insects, reducing the need for chemical pesticides and promoting sustainable farming practices.
Used in Allelopathic Plant Interactions:
In the field of plant biology, 3,4-Dihydro-2H-1,4-benzoxazin-7-ol is used to study its allelopathic effects on competing plant species. It influences the growth and development of neighboring plants, providing insights into plant-plant interactions and potential applications in managing plant competition in agricultural systems.

Upstream product

• 67193-97-9 7-hydroxy-2H-benzo[b][1,4]oxazin-3(4H)-one 
• 6529-94-8 7-methoxy-2H-1,4-benzoxazin-3-one 
• 93735-22-9 7-methoxy-3,4-dihydro-2H-benzo-[b][1,4]oxazine 

Downstream Products

• 1338595-02-0 C₁₈H₁₅NO₃ 
• 1027218-05-8 (7-oxiranylmethoxy-2,3-dihydro-benzo[1,4]oxazin-4-yl)-phenyl-methanone 
• 258524-52-6 4-benzoyl-7-hydroxy-3,4-dihydro-2H-1,4-benzoxazine 

Relevant articles and documents

Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis

Angiogenesis is vital for solid tumor growth, and its prevention is a proven strategy for the treatment of disease states such as cancer. The vascular endothelial growth factor (VEGF) pathway provides several opportunities by which small molecules can act as inhibitors of endothelial proliferation and migration. Critical to these processes is signaling through VEGFR-2 or the kinase insert domain receptor (KDR) upon stimulation by its ligand VEGF. Herein, we report the discovery of 2,3-dihydro-1,4-benzoxazines as inhibitors of intrinsic KDR activity (IC50 50 a potent (KDR: a promising platform for generating kinase-based antiangiogenic therapeutic agents.

Synthesis of oxypropanolamine derivatives of 3,4-dihydro-2H-1,4- benzoxazine, β-adrenergic affinity, inotropic, chronotropic and coronary vasodilating activities

A series of oxypropanolamine derivatives of 3,4-dihydro-2H-1,4- benzoxazine were synthesized and evaluated for inotropic, chronotropic and coronary vasodilating activities in the canine heart, affinity to β1- adrenergic receptor in turkey erythrocytes and affinity to the β2- adrenergic receptor in the rat lung. Among these compounds, 4-acetyl-6-(3- tert-butylamino-2-hydroxy)propoxy-3,4-dihydro-2H-1,4-benzoxazine showed 2.1- fold more potent affinity to the β1 receptor than propranolol and 7-(3- tert-butylamino-2-hydroxy)propoxy-N-butyryl-3,4-dihydro-2H-1,4-benzoxazine showed 2.5-fold more potent affinity to the β2 receptor and furthermore 4 386-fold more potent selectivity to the β2 receptor than propranolol. In addition, 4-acetyl-6-[3-(3,4-dimethoxybenzyl)amino-2-hydroxy]propoxy-3,4- dihydro-2H-1,4-benzoxazine showed 1.1-fold more potent affinity to the β1 receptor than propranolol and also 1 147-fold more potent selectivity to the β1 receptor. With a few exceptions, negative inotropic and chronotropic actions of these compounds were dependent on the size of the 4-substituent obeying the order: unsubstituted 1-adrenoceptor nor coronary vasodilator action related with affinity to β2-adrenoceptor were observed. 4-acetyl-7- [3-(3,4-dimethoxybenzyl)amino-2-hydroxy]propoxy-3,4-dihydro-2H-1,4- benzoxazine exerted potent positive inotropic, chronotropic and coronary vasodilating actions. The inotropic and chronotropic actions of the latter compound may be attributed to the release of intrinsic catecholamines, as concluded by the absence of β1-adrenoceptor affinity and disappearance of activity in the presence of a β-blocker.

Process for lightening the skin or treating pigmental blemishes using a composition containing benzomorpholine or 3,4-dihydro-2H-1,4-benzoxazine derivatives

A topical process for lightening the skin or treating pigmental blemishes consisting in applying to the part of the skin to be treated a composition containing, as active compounds hydroxybenzomorpholines and derivatives thereof corresponding to the following formula: STR1 in which: R1 represents a hydrogen atom or an alkyl radical having from 1 to 4 carbon atoms, and R2 represents a hydroxyl radical in the 6- or 7-position.